Abstract：
:We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for ≥2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disease (74%). Median follow-up of survivors was 106 (range, 24-192) months. Overall survival at 10 years after HCT was 94% (95% confidence intervals, 89-97%) and 80% (67-91%) for patients receiving HCT in CR1 and CR2, respectively. The cumulative incidence of relapse at 10 years after HCT was 6% (3-10%) and 10% (3-20%) and that of nonrelapse mortality was 5% (2-9%) and 11% (4-21%), respectively. On multivariate analysis, HCT in CR2 (vs CR1), older age at transplantation and poor cytogenetic risk disease were independent predictors of late mortality and adverse disease-free survival. The use of growth factors to promote engraftment after HCT was the only risk factor for relapse. Relative mortality of these 2-year survivors was comparable to that of age-, race- and gender-matched normal population. Patients who receive autologous HCT for AML in CR1 or CR2 and remain in remission for ≥2 years have very favorable long-term survival. Their mortality rates are similar to that of the general population.
journal_name
Bone Marrow Transplantjournal_title
Bone marrow transplantationauthors
Majhail NS,Bajorunaite R,Lazarus HM,Wang Z,Klein JP,Zhang MJ,Rizzo JDdoi
10.1038/bmt.2010.115subject
Has Abstractpub_date
2011-03-01 00:00:00pages
385-92issue
3eissn
0268-3369issn
1476-5365pii
bmt2010115journal_volume
46pub_type
杂志文章,多中心研究abstract：:Leukemic relapse remains the most frequent reason for treatment failure in patients with acute myeloblastic leukemia (AML) treated with autologous blood stem cell transplantation (ABSCT). The aim of this study was to evaluate the possible role of autologous bone marrow transplant (ABMT) in patients with AML who relaps...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：
更新日期：1996-12-01 00:00:00
abstract：:Hematopoietic growth factors like G-CSF or GM-CSF have been shown to shorten the period of severe neutropenia after HD chemotherapy and autologous BMT, and are now widely used to mobilize hemopoietic stem cells into peripheral blood. In order to evaluate the possibility of delaying G-CSF administration after transplan...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：1996-04-01 00:00:00
abstract：:As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7) and unrelated donors (n...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2008.85
更新日期：2008-07-01 00:00:00
abstract：:Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/sj.bmt.1703721
更新日期：2002-11-01 00:00:00
abstract：:Allogeneic SCT is curative for bone marrow failure in Fanconi anemia (FA) patients but the optimal conditioning regimen is undetermined. We report here our experience with 56 FA patients who underwent allogeneic matched related SCT. The conditioning regimen varied according to time of SCT and disease status at SCT; 22...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2008.114
更新日期：2008-08-01 00:00:00
abstract：:We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 mont...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1994-02-01 00:00:00
abstract：:Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past d...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/bmt.2014.114
更新日期：2014-10-01 00:00:00
abstract：:HLA disparity between hematopoietic stem cell (HSC) donor and recipient triggers T-cell and NK-cell allorecognition, and induces the GVHD, GVL effect and/or may cause an engraftment failure. This review will cover the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/bmt.2008.288
更新日期：2008-10-01 00:00:00
abstract：:Increased understanding of minor histocompatibility complex (MiHC) antigen presentation to donor T cells may permit methods to modulate graft-versus-host disease (GVHD), a major complication of allogeneic bone marrow transplantation (BMT). Previously, we described the importance of B cells as antigen presenting cells ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1995-08-01 00:00:00
abstract：:Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2010.217
更新日期：2011-07-01 00:00:00
abstract：:It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patien...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,meta分析,评审
doi：10.1038/bmt.2009.41
更新日期：2009-10-01 00:00:00
abstract：:Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1990-07-01 00:00:00
abstract：:There is a known increased risk of skin cancer in the adult population after hematopoietic stem cell transplantation (HSCT). However, late dermatologic effects that children may experience after HSCT have not been well described. The primary objective of this study was to characterize nevi and skin cancers affecting c...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/bmt.2017.57
更新日期：2017-07-01 00:00:00
abstract：:We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin. The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotectio...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：
更新日期：1991-01-01 00:00:00
abstract：:We report the response to the ABL kinase inhibitor imatinib mesylate (STI571) in a patient with chronic myeloid leukemia (CML) who relapsed twice after dose-reduced allogeneic stem cell transplantation (alloSCT) for B lymphoid blast crisis (BC) and failed to develop an antileukemic response despite grade 3 graft-versu...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703885
更新日期：2003-04-01 00:00:00
abstract：:The majority of adult patients have sexual concerns after post-haematopoietic cell transplantation. Even so, health-care professionals (HCP) do not routinely discuss these problems. We, therefore, surveyed all the members of the European Society for Blood and Marrow Transplantation to evaluate the barriers and facilit...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/s41409-017-0027-y
更新日期：2018-03-01 00:00:00
abstract：:A 41-year-old male with IgG kappa multiple myeloma is described. He developed a free gamma heavy chain without an accompanying light chain following high-dose chemotherapy and autologous peripheral blood stem cell transplantation. The free gamma heavy chain was detected in serum and urine specimens 2 months after tran...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702850
更新日期：2001-03-01 00:00:00
abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,多中心研究
doi：10.1038/sj.bmt.1704579
更新日期：2004-08-01 00:00:00
abstract：:We performed a randomized study to compare 'G-CSF alone' (administered at dose of 10 mcg/kg/day) and 'cyclophosphamide plus G-CSF' (cyclophosphamide at dose of 4 g/m(2) and G-CSF at dose of 10 microg/kg/day), as PBPC mobilization schedules in 52 patients with NHL or HD. Randomization was stratified according to the am...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.bmt.1703912
更新日期：2003-05-01 00:00:00
abstract：:To determine the role of biomarkers in the clinical management of respiratory complications (RC) in hematopoietic stem cell transplantation (HSCT) recipients, we have prospectively evaluated a cohort of 175 patients followed-up for 1 year after HSCT. To avoid misinterpretation, we have excluded both unidentified respi...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/bmt.2016.280
更新日期：2017-03-01 00:00:00
abstract：:The indolent non-Hodgkin's lymphomas are theoretically curable through allogeneic haematopoietic stem cell transplantation (allo-HSCT). The applicability of standard conditioning allo-HSCT is, however, restricted by its toxicity. Recently, reduced-intensity conditioning regimens have demonstrated efficacy with signifi...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703898
更新日期：2003-04-01 00:00:00
abstract：:Salivary gland dysfunction is a common sequela of hematopoietic progenitor cell transplantation (HPCT). The investigation of major salivary gland dysfunction with sodium pertechnetate scintigraphy is a non-invasive method that provides images of the parotid and submandibular glands. In this prospective trial, 20 HPCT ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705351
更新日期：2006-05-01 00:00:00
abstract：:Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was st...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,随机对照试验
doi：10.1038/bmt.2009.337
更新日期：2010-08-01 00:00:00
abstract：:Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate dono...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705164
更新日期：2005-12-01 00:00:00
abstract：:The era of reduced-intensity allogeneic stem cell transplantation, with its emphasis on older patients, has created new challenges in the management of what is now an older related stem cell donor population. These donors are now on average no less than 10 years older than in the mid-1990s. Donors over 70 years of age...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/bmt.2016.201
更新日期：2017-01-01 00:00:00
abstract：:We report here a 6-month-old boy with severe congenital neutropenia (SCN) successfully treated by cord blood stem cell transplantation (CBSCT) from an unrelated donor. He had recurrent life-threatening respiratory infection due to severe neutropenia that was refractory to recombinant human granulocyte colony-stimulati...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704439
更新日期：2004-05-01 00:00:00
abstract：:We report results of a thiotepa-based conditioning in haploidentical stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-CY) and antithymocyte globulin (ATG), for unmanipulated peripheral blood stem cell (PBSC) transplants, in 80 patients with hematological malignancies. Patients in complete...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/s41409-019-0726-7
更新日期：2020-04-01 00:00:00
abstract：:Acute inflammatory demyelinating polyneuropathy (AIDP) appeared in two patients following allogeneic bone marrow transplantation (BMT). In one transplanted patient (but not in the donor) T cells were sensitized against peripheral nervous system myelin. This could reflect a change in the T cell repertoire in a differen...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1991-10-01 00:00:00
abstract：:Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2009.97
更新日期：2010-01-01 00:00:00
abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1996-11-01 00:00:00
